PhaseBio Overview
- Year Founded
-
2002
- Status
-
Public
- Employees
-
60
- Stock Symbol
-
2K4
- Investments
-
2
- Share Price
-
$0.07
- (As of Wednesday Closing)
PhaseBio General Information
Description
PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.
Contact Information
Website
www.phasebio.comCorporate Office
- One Great Valley Parkway
- Suite 30
- Malvern, PA 19355
- United States
Corporate Office
- One Great Valley Parkway
- Suite 30
- Malvern, PA 19355
- United States
PhaseBio Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.07 | $0.09 | $0.07 - $3.02 | $3.5M | 49.9M | -$2.13 |
PhaseBio Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 17,365 | 78,942 | ||
| Revenue | 818 | 10,831 | 0 | 2,361 |
| EBITDA | (100,255) | (126,745) | (96,849) | (39,553) |
| Net Income | (102,840) | (131,071) | (98,565) | (39,247) |
| Total Assets | 22,166 | 60,540 | 50,357 | 82,494 |
| Total Debt | 5,372 | 8,320 | 14,066 | 16,477 |
PhaseBio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PhaseBio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
PhaseBio Comparisons
Industry
Financing
Details
PhaseBio Competitors (112)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abeona Therapeutics | Corporation | Cleveland, OH | ||||
| UCB | Corporation | Brussels, Belgium | ||||
| Travere Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Corvus Pharmaceuticals | Formerly VC-backed | Burlingame, CA | ||||
| TG Therapeutics | Corporation | Morrisville, NC |
PhaseBio Patents
PhaseBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230173030-A1 | Vasoactive intestinal peptide fusion proteins for the treatment of covid-19 | Inactive | 05-May-2020 | ||
| JP-2023071692-A | Metalloenzyme inhibitor compounds | Pending | 29-Dec-2016 | ||
| ES-2909074-T3 | Elp fusion proteins for controlled and sustained release | Active | 06-May-2016 | ||
| EP-3452021-A1 | Elp fusion proteins for controlled and sustained release | Active | 06-May-2016 | ||
| EP-3452021-B1 | Elp fusion proteins for controlled and sustained release | Active | 06-May-2016 | A61K9/0024 |
PhaseBio Executive Team (15)
| Name | Title | Board Seat |
|---|---|---|
| Jonathan Mow | Chief Executive Officer & Board Member | |
| John Sharp | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting | |
| Jonathan Birchall | Executive | |
| Susan Arnold Ph.D | Senior Vice President | |
| John Lee Ph.D | Chief Medical Officer |
PhaseBio Board Members (22)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alex Sapir | Self | Board Member | |
| Caroline Loewy | Self | Board Member | |
| Clay Thorp | Hatteras Venture Partners | Chairman & Board Member | |
| Edmund Harrigan MD | Self | Board Member | |
| Jonathan Mow | PhaseBio | Chief Executive Officer & Board Member |
PhaseBio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
PhaseBio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
PhaseBio Investments (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Viamet Pharmaceuticals (Intellectual properties) | 13-Jan-2020 | Buildings and Property | |||
| ImmunoForge | 01-Mar-2019 | Early Stage VC | Drug Discovery |
PhaseBio ESG
Risk Overview
Risk Rating
Updated April, 30, 2021
40.84 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,042
Rank
Percentile
Pharmaceuticals
Industry
of 947
Rank
Percentile
Pharmaceuticals
Subindustry
of 452
Rank
Percentile
PhaseBio FAQs
-
When was PhaseBio founded?
PhaseBio was founded in 2002.
-
Who is the founder of PhaseBio?
Don Rose and Ashutosh Chilkoti Ph.D are the founders of PhaseBio.
-
Who is the CEO of PhaseBio?
Jonathan Mow is the CEO of PhaseBio.
-
Where is PhaseBio headquartered?
PhaseBio is headquartered in Malvern, PA.
-
What is the size of PhaseBio?
PhaseBio has 60 total employees.
-
What industry is PhaseBio in?
PhaseBio’s primary industry is Drug Delivery.
-
Is PhaseBio a private or public company?
PhaseBio is a Public company.
-
What is PhaseBio’s stock symbol?
The ticker symbol for PhaseBio is 2K4.
-
What is the current stock price of PhaseBio?
As of 02-Nov-2022 the stock price of PhaseBio is $0.07.
-
What is the current market cap of PhaseBio?
The current market capitalization of PhaseBio is $3.5M.
-
What is PhaseBio’s current revenue?
The trailing twelve month revenue for PhaseBio is $818K.
-
Who are PhaseBio’s competitors?
Abeona Therapeutics, UCB, Travere Therapeutics, Corvus Pharmaceuticals, and TG Therapeutics are some of the 112 competitors of PhaseBio.
-
What is PhaseBio’s annual earnings per share (EPS)?
PhaseBio’s EPS for 12 months was -$2.13.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
